Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

79 results about "Wild type cell" patented technology

Wild type barm cells contain VRP1 cistron that encodes Verprolin protein. VRP1 protein is the barm ( S. cerevisiae ) ortholog of human Wiskott-Aldrich syndrome protein ( WASP ) -interacting protein ( WIP ) .

Nitrogen-containing heterocyclic compound, pharmaceutical composition thereof and application thereof

Disclosed is a nitrogen-containing heterocyclic compound, pharmaceutical composition thereof and application thereof. The present disclosure provides a nitrogen-containing heterocyclic compound of formula I, a pharmaceutically acceptable salt thereof, a prodrug thereof, a stereoisomer thereof, a tautomer thereof or an isotopically labeled compound thereof. The nitrogen-containing heterocyclic compounds as represented in Formula I in the present disclosure have good inhibitory effects on cells of various mutations such as KRAS G12C, KRAS G12D, KRAS G12V, KRAS Q61H and other mutations, as well as on KRAS-amplified wild-type cells, and are expected to treat and / or prevent a wide range of diseases associated with Ras.
Owner:YINGLI PHARMA (BVI) LTD

Mutant cytochrome p450 enzymes with enhanced peroxygenase activity and / or altered product selectivity

The present invention relates to mutant enzymes with enhanced properties and processes for oxidation of organic compound substrates using such enzymes. More specifically, provided herein are mutations in cytochrome P450 enzymes that enhance their peroxygenase activity and / or alter product selectivity compared to wild-type cytochrome P450 enzymes. Uses for such mutant cytochrome P450 enzymes are also provided, such as for biocatalytic oxidation of carbon-hydrogen bonds via a peroxygenase pathway, or for oxidizing a substrate which is an organic compound.
Owner:UNIVERSITY OF ADELAIDE

Nitrogen-containing heterocyclic compound as well as pharmaceutical composition and application thereof

The invention discloses a nitrogen-containing heterocyclic compound as well as a pharmaceutical composition and application thereof. The invention provides a nitrogen-containing heterocyclic compound as shown in a formula I, and pharmaceutically acceptable salts, prodrugs, stereoisomers, tautomers or isotope compounds thereof. According to the present invention, the nitrogen-containing heterocyclic compound has good inhibition effects on a variety of mutations such as KRASG12C, KRASG12D, KRASG12V, KRASQ61H and the like, and the wild type cells amplified by KRAS, and is expected to be used for treating and / or preventing a variety of Ras-related diseases. # imgabs0 #
Owner:SHANGHAI YINGLI PHARMACEUTICAL CO LTD

Application of MDH2 inhibitor in preparation of preparation for reducing toxicity of fumonisins

The invention discloses application of an MDH2 inhibitor in preparation of a preparation for reducing toxicity of fumonisins, and belongs to the technical field of biology. A fumonisins treatment experiment is carried out on MDH2 gene mutant cells and wild type MDH2 gene cells, and the result shows that the cell activity of the MDH2 gene mutant cells is remarkably improved by 15.2% compared with that of wild type MDH2 gene expression cells under the condition that the fumonisins concentration is 100 micrograms / mL, the cell apoptosis rate is remarkably reduced by 7.76%, and the cell apoptosis rate can be reduced by 7.76%. Therefore, the MDH2 gene mutation can improve the tolerance to the fumonisins. In addition, the LW6 inhibitor is used for inhibiting the MDH2 activity of the wild type IPEC-J2 cell, and the tolerance of the cell to the fumonisins can also be improved. The invention provides a potential solution way for preventing adverse reaction caused by fumonisins, and provides a theoretical basis for preventing and controlling harm of FB1 to food and animal husbandry.
Owner:AGRO BIOLOGICAL GENE RES CENT GUANGDONG ACADEMY OF AGRI SCI

Method for producing proheparin, heparan sulfate and heparin in yeast

The present invention relates to a recombinant yeast cell that produces UDP-D-glucuronic acid and / or UDP-N-acetyl-D-glucosamine compared to a wild type cell of the recombinant yeast cell; and optionally, the yield of 3 '-phosphate-adenylate sulfuric acid is increased. The invention also relates to a method for producing heparan sulfate, which comprises a step of culturing the recombinant yeast cell, further relates to an application of the non-invasive recombinant yeast cell for producing heparan sulfate, and finally relates to heparan sulfate obtained by applying the method.
Owner:GENTIS FINE CHEMICALS CO LTD

Application of Aars1 gene in regulation and control of expression of exogenous recombinant protein

The invention provides application of an Aars1 gene in regulation and control of expression of an exogenous recombinant protein, and belongs to the technical fields of recombinant protein expression, gene engineering and cell culture. According to the CHO cell line, shRNA fragments of targeted Aars1 genes are inserted and integrated into piggyBac transposon vectors, a recombinant vector for inhibiting / silencing the Aars1 genes and an Aars1 low-expression CHO cell line are constructed, the CHO cell line can remarkably reduce the mRNA expression level of the Aars1, meanwhile, the CHO cell line serves as a host cell for recombinant protein expression, and compared with a wild type CHO cell line, the CHO cell line has the advantages that the expression level of the CHO cell line is greatly improved; the recombinant adalimumab can improve the expression quantity of recombinant protein (the expression quantity of the recombinant adalimumab is increased by 3.1 + / -0.18 times), effectively overcomes the problem of low expression level of the existing CHO cell expression system, and can be used for further constructing a recombinant protein expression system or kit.
Owner:XINXIANG MEDICAL UNIV +1

Application of MDH2 gene and inhibitor thereof in resisting ZEA toxin

The invention discloses an application of an MDH2 gene and an inhibitor thereof in resisting ZEA toxin, and relates to the technical field of biology. An MDH2 gene deletion cell line is obtained through CRISPR gene editing, and compared with a wild type MDH2 gene expression cell, under the influence of ZEA, the cell activity of the MDH2 gene deletion cell line is remarkably improved, and the cell apoptosis rate is remarkably reduced. In addition, the LW6 inhibitor is used for inhibiting the MDH2 activity of wild type IPEC-J2 cells, and the tolerance of the cells to ZEA can also be improved. Therefore, through knockout, mutation or activity inhibition of the MDH2 gene, the ZEA resistance of people, animals and plants can be improved. The invention provides a potential solution way for solving untoward effects caused by ZEA (Zinc Ethylenediamine).
Owner:AGRO BIOLOGICAL GENE RES CENT GUANGDONG ACADEMY OF AGRI SCI +1

Biotechnological production of desferrioxamines and analogs thereof

A recombinant microbial cell is capable of producing at least one compound having structural Formula II from a carbon source:In Formula II, n=2-3; R1=H or COCH3 or CH2CH2COX with X=OH or O—; R2=CH3 or CH2CH2COX with X=OH or O— where the cell comprises a genetic modification to increase activity relative to its wild-type cell of E4 where E4 is a desferrioxamine or bisucaberin synthetase (EC 6.3.-.-) (E4i) capable of converting N5-aminopentyl-N-(hydroxy)-succinamic acid to desferrioxamine B or H or at least one other linear desferrioxamine or bisucaberin according to Formula II.
Owner:EVONIK OPERATIONS GMBH

Tetra-heterocyclic compound as well as preparation method and application thereof

The invention discloses a tetra-heterocyclic compound as well as a preparation method and application thereof, and particularly discloses a compound as shown in a formula I, and a stereoisomer or pharmaceutically acceptable salt thereof. The tetra-heterocyclic compound provided by the invention has good proliferation inhibition activity on at least one of NCI-H358 cells, Capan-1 cells and AsPC-1 cells containing KRAS mutation, has relatively weak proliferation inhibition activity on KRAS wild type PC-9 cells, and is expected to treat and / or prevent KRAS mediated diseases.
Owner:SHANGHAI ALLIST PHARM CO LTD

Biaromatic ring amide compound and application thereof

The invention discloses a biaromatic ring amide compound and application thereof. The invention provides a compound as shown in a formula I or pharmaceutically acceptable salt thereof. The small molecule compound provided by the invention has a good inhibition effect on Pol theta enzyme and / or PARP1 enzyme, further has a relatively strong proliferation inhibition effect on DLD1BRCA2- / -cells, has an extremely weak proliferation inhibition effect on DLD1 wild-type cells and shows very good selectivity, and further, the compound provided by the invention can be used for overcoming drug resistance, reducing the dosage and reducing the toxic and side effects, and has a good application prospect. The purposes of expanding indications and improving the treatment effect are achieved. # imgabs0 #
Owner:HANGZHOU SYNRX THERAPEUTICS BIOMEDICAL TECH CO LTD

Mutant cytochrome p450 enzymes with enhanced peroxygenase activity and / or altered product selectivity

The present invention relates to mutant enzymes with enhanced properties and methods of using such enzymes to oxidize organic compound substrates. More specifically, provided herein are mutations in cytochrome P450 enzymes that enhance their peroxygenase activity and / or alter product selectivity as compared to wild-type cytochrome P450 enzymes. Also provided are uses of such mutant cytochrome P450 enzymes, e.g., for biocatalytic oxidation of carbon-hydrogen bonds by a peroxygenase pathway, or for oxidation of organic compound substrates.
Owner:UNIVERSITY OF ADELAIDE

Nitrogen-containing heterocyclic compound, pharmaceutical composition thereof and application thereof

Disclosed is a nitrogen-containing heterocyclic compound, pharmaceutical composition thereof and application thereof. The present disclosure provides a nitrogen-containing heterocyclic compound of formula I, a pharmaceutically acceptable salt thereof, a prodrug thereof, a stereoisomer thereof, a tautomer thereof or an isotopically labeled compound thereof. The nitrogen-containing heterocyclic compounds as represented in Formula I in the present disclosure have good inhibitory effects on cells of various mutations such as KRAS G12C, KRAS G12D, KRAS G12V, KRAS Q61H and other mutations, as well as on KRAS-amplified wild-type cells, and are expected to treat and / or prevent a wide range of diseases associated with Ras.
Owner:YINGLI PHARMA (BVI) LTD

Chimeric antigen receptor targeting EGFRvIII and application thereof

The invention discloses a chimeric antigen receptor targeting EGFRvIII and application of the chimeric antigen receptor. The chimeric antigen receptor sequentially comprises an EGFRvIII targeting nucleic acid aptamer, a transmembrane domain and an intracellular signal domain from an N end to a C end, the EGFRvIII targeted nucleic acid aptamer is an EGFRvIII specific DNA aptamer obtained on the basis of SELEX (systematic evolution of ligands by exponential enrichment) screening, can only be combined with an extracellular domain of the EGFRvIII, and is not combined with an EGFR (epidermal growth factor receptor) wild type; the intracellular signal domain comprises a costimulatory signal domain and an activation signal domain, the C end of the costimulatory signal domain is connected with the N end of the activation signal domain, and the EGFRvIII specific nucleic acid aptamer screened based on SELEX is adopted as a targeting domain, can only be specifically combined with the extracellular domain of EGFRvIII positive tumor cells, and is not subjected to cross combination with EGFR wild cells and normal cells, so that the EGFRvIII specific nucleic acid aptamer can be used for detecting EGFRvIII positive tumor cells, and the EGFRvIII specific nucleic acid aptamer can be used for detecting EGFRvIII positive tumor cells. The problem of off-target killing caused by the fact that a common antibody scFv fragment of a traditional chimeric antigen receptor (CAR) is easily combined with a wild type EGFR is fundamentally avoided.
Owner:CARRIAGE PHARM (BEIJING) CO LTD

Host immune cells engineered to overexpress a FOXK1 polypeptide

T lymphocytes play a key role in the immune response and their functions are intimately linked to metabolic programs. During immune responses, T cells undergo a metabolic reprogramming notably characterized by an increased aerobic glycolysis. Using a quantitative phosphoproteomic approach, the inventors have identified a new transcription factor called Foxk1 as being highly phosphorylated in T cells upon T Cell Receptor (TCR) engagement. The results also indicate that Foxk1 phosphorylation and nuclear translocation is dependent of the AKT-mTOR kinase activities. Using T-cell specific Foxk1 deficient mice (Foxk1- / -), we demonstrated that Foxk1 is required for full T cell activation. Foxk1-deficient T cells exhibited reduced proliferation and cytokine secretion following TCR stimulation. Furthermore, T cells from Foxk1- / - mice were less prone to acquire an effector like phenotype than wild-type cells when challenged in vivo. Conversely, Foxk1 overexpression in T cells enhanced their effector functions in a TCR-dependent manner. In CD8+ T cells, this effect also results into enhanced cancer cell killing capacity in vitro, and improved tumor rejection in vivo. Altogether, these results indicated that Foxk1 is a major regulator of T cell metabolism and thus, of T cell effector functions. Thus, the present invention relates to host immune cells engineered to overexpress a Foxk1 polypeptide and their use of the treatment of cancer.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +3

Method of using human spheroids for drug discovery

The present invention discloses, in one embodiment, a method of using human induced pluripotent stem cells to generate three-dimensional human organ tissue for therapeutic drug toxicity and discovery⋅. In one embodiment, a high throughput microtiter plate is loaded with both wild type and Rett disease 3D spheroids and exposed to a drug library, and activity is measured and analyzed for disease rescue to wild type cell behavior.
Owner:AXOSIM INC

Biotechnical production of ω-functionalized carboxylic acids and their esters

This invention relates to the biotechnological production of ω-functionalized carboxylic acids and their esters. Microbial cells are provided for the production of at least one ω-functionalized carboxylic acid ester from at least one alkane, wherein the cells are genetically modified relative to wild-type cells to increase the expression of: (i) an enzyme E1 capable of converting the alkane to the corresponding 1-alkanol; (ii) an enzyme E2 capable of converting the 1-alkanol of (i) to the corresponding 1-alkanal; (iii) an enzyme E3 capable of converting the 1-alkanal of (ii) to the corresponding alkanoic acid; (iv) an enzyme E4 capable of converting the alkanoic acid of (iii) to the corresponding alkanoic acid ester; and (iv) an enzyme E5 capable of converting the alkanoic acid ester of (iv) to the corresponding ω-hydroxy-alkanoic acid ester, and wherein the cells do not contain an increase relative to wild-type cells of the expression of the following enzymes selected from the group consisting of: 20 -E 24 Genetic modification of expression of at least one of them: -E 20 Acyl-ACP thioesterase, -E 21 Acyl-CoA thioesterase, -E 22 Acyl-CoA:ACP transacylase, -E 23 Polyketide synthase, and -E 24 Hexanoic acid synthase.
Owner:EVONIK OPERATIONS GMBH

Biotechnological production of deferoxamine and analogs thereof

PendingCN119301244AHigh production performance featuresreduce manufacturing costTransferasesMicroorganism based processesSuccinic acidDeferoxamin
The present invention relates to a recombinant microbial cell for the production of at least one compound of structural formula II from a carbon source: # imgabs0 # formula IIn = 2-3R1 = H or COCH3 or CH2CH2COX wherein X = OH or O-R2 = CH3 or CH2CH2COX wherein X = OH or O-wherein said cell comprises a genetic modification to increase the activity of E4 relative to its wild type cell wherein: E4 is deferoxamine or bisukaline synthetase (EC 6.3.-) (E4i), the present invention relates to deferoxamine compounds capable of converting N5-aminopentyl-N-(hydroxy)-succinamic acid to deferoxamine B or H or at least one other linear deferoxamine or bisukaline according to formula II.
Owner:EVONIK OPERATIONS GMBH

Cell-type selective immunoprotection of cells

This disclosure relates to formulations comprising one or more cells, wherein the cells of the formulation are modified to conditionally express: (i) increased levels of one or more immune checkpoint proteins compared to corresponding wild-type cells; (ii) decreased levels of one or more HLA-I proteins compared to corresponding wild-type cells; or a combination of (i) and (ii). This disclosure further relates to methods and constructs for producing said cell formulations, and methods for administering said cell formulations to subjects in need.
Owner:UNIVERSITY OF ROCHESTER

Application of porcine TAB1 knockout cell line in promotion of PRV proliferation

The invention belongs to the technical field of molecular biology, and particularly relates to application of a porcine TAB1 knockout cell line in promotion of PRV proliferation. The porcine TAB1 knockout cell line is obtained by transfecting a porcine TAB1 gene knockout plasmid into a cell and then culturing; the porcine TAB1 gene knockout plasmid is obtained by inserting a nucleotide sequence shown as a sequence 1 in a sequence table between a Hind III restriction enzyme cutting site of a Px459M plasmid and a Bbs I restriction enzyme cutting site farthest from the Hind III restriction enzyme cutting site. Compared with a wild type 3D4 / 21 cell line, the porcine TAB1 knockout cell line obviously promotes PRV virus proliferation, can be used for PRV proliferation research, and is further applied to preparation of PRV vaccines.
Owner:INST OF ANIMAL SCI & VETERINARY MEDICINE SHANDONG ACADEMY OF AGRI SCI +1

Construction of RNF31 gene knockout cell line and application of RNF31 gene knockout cell line as foot and mouth disease virus vaccine production cell line

The invention belongs to the field of gene engineering, and particularly relates to construction of an RNF31 gene knockout cell line and application of the RNF31 gene knockout cell line as a foot-and-mouth disease virus vaccine production cell line. The method comprises the following steps: firstly, designing two sgRNA sequences at an RNF31 exon by utilizing a CRISPR / Cas9 technology, and connecting with a pX459-puro vector to construct a recombinant plasmid; the method comprises the following steps: transfecting a PK-15 cell with pX459-RNF31-sgRNA, and screening under the action of puromycin, so as to obtain the RNF31 gene knockout cell line. Compared with a wild type cell, the RNF31 gene knockout cell line remarkably promotes FMDV replication and can be used as a production cell line of a foot and mouth disease virus vaccine; and data support is provided for further researching a mechanism of inhibiting FMDV replication by RNF31.
Owner:LANZHOU VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES(LANZHOU BRANCH CENTER OF CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENTER)

Use of t cells overexpressing prdm16 in preparation of drugs for resisting tumor or treating infectious diseases

This invention discloses the application of T cells overexpressing PRDM16 in the preparation of anti-tumor or infectious disease drugs. Through experiments, this invention verifies that overexpression of PRDM16 enhances the in vivo and in vitro activity of T cells. It was found that in vitro overexpression of PRDM16 significantly enhances the killing effect of T cells on target cells. In vivo reinfusion of PRDM16 has stronger anti-tumor and anti-infection functions compared to wild-type T cells. Therefore, it can be used in malignant tumors and infectious diseases to enhance the efficacy of T cell adoptive therapy and solve the defect of T cell adoptive therapy where the killing power of target cells is suppressed due to environmental influences.
Owner:XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV

Application of IRF2 gene in resisting chicken chronic respiratory disease

The invention discloses an application of a poultry IRF2 gene, and the poultry IRF2 gene is used for inhibiting the replication of Mycoplasma gallisepticum (MG) in host cells and the expression of virulence protein, so that the poultry chronic respiratory disease (CRD) caused by MG infection can be resisted. According to the application disclosed by the invention, the IRF2 gene in the chicken macrophage HD11 is interfered by utilizing a gene silencing technology, after MG challenge, the replication level and virulence protein expression of intracellular MG are obviously lower than those of wild type cells, inflammatory response and cell apoptosis of HD11 are obviously inhibited, and cell proliferation is promoted. The overexpressed IRF2 gene in the cell, the replication of the MG in the cell and the expression of the virulence protein are obviously enhanced, which indicates that the IRF2 gene is a susceptible gene of the MG, and the cell has an MG resistance phenotype after being knocked down, so that the replication of the MG and the expression of the virulence protein can be effectively inhibited. Therefore, the IRF2 gene can be used as a new target for development of vaccine drugs for inhibiting MG replication and research on disease resistance breeding.
Owner:HUAZHONG AGRI UNIV

Use of STK31 kinase inhibitor ciclopirox compounds for treatment of pancreatic ductal adenocarcinoma

The invention belongs to the technical field of medicines, and particularly relates to application of a ciclopirox compound in a medicine for treating cancers induced by KRAS G12D mutation, and the cancers comprise pancreatic ductal adenocarcinoma and colorectal cancer. The compound can obviously inhibit the activity of KRAS mutant pancreatic cancer cells, has weak inhibition on KRAS wild type cells, and shows potential targeted therapy advantages. Animal experiment results show that the ciclopirox compound provided by the invention can effectively inhibit tumor growth and down-regulate phosphorylated STK31 protein expression. The composition is clear in component and simple and convenient to prepare, and provides a new strategy for overcoming the drug resistance of pancreatic cancer.
Owner:THE SEVENTH AFFILIATED HOSPITAL SUN YAT SEN UNIV SHENZHEN

Application of TP63 gene in improving expression quantity of exogenous recombinant protein

The invention belongs to the technical field of gene engineering, and particularly relates to application of a TP63 gene in improving the expression quantity of exogenous recombinant protein, and the nucleotide sequence of the TP63 gene is shown as SEQ ID NO.1. According to the invention, the TP63 overexpression vector is creatively applied to construction of a recombinant protein expression system, the TP63 overexpression vector is transfected into CHO cells to construct a CHO cell line for overexpressing TP63, and the CHO cell line can significantly improve the expression level of TP63 protein. Meanwhile, the CHO cell line is used as a host cell for recombinant protein expression, compared with a wild type CHO cell line, the expression quantity of recombinant protein can be increased, and the problem that the expression level of antibody expression quantity in an existing CHO cell expression system is low is effectively solved.
Owner:XINXIANG MEDICAL UNIV

VP2 protein mutated O-type foot-and-mouth disease recombinant virus as well as preparation and application thereof

The invention belongs to the technical field of biology, and particularly relates to a VP2 protein mutated O-type foot-and-mouth disease recombinant virus as well as preparation and application thereof. The 88th lysine residue of O-type FMDV-VP2 protein is mutated into arginine residue by using a reverse genetic manipulation technology to successfully rescue the O-type foot-and-mouth disease recombinant virus strain rO-VP2K88R, and compared with an O-type foot-and-mouth disease wild type virus strain rO-WT rescued by using the reverse genetic manipulation technology, the recombinant virus strain provided by the invention has the advantages that the recombinant virus strain has the advantages that the yield is high; the growth replication capacity in wild type PK-15 cells is remarkably reduced, and the pathogenicity to suckling rats is also remarkably reduced. Therefore, the obtained O-type foot-and-mouth disease recombinant virus strain rO-VP2K88R possibly has certain immunogenicity and is expected to become a vaccine candidate strain, and a basic research material is provided for researching the foot-and-mouth disease vaccine candidate strain.
Owner:LANZHOU VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES(LANZHOU BRANCH CENTER OF CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENTER)

IPEC-J2 cell strain capable of stably expressing PED virus nucleocapsid protein truncated fragment and application of IPEC-J2 cell strain

The invention relates to a bioengineering technology, and aims to provide an IPEC-J2 cell strain for stably expressing a PED virus nucleocapsid protein truncated fragment and application of the IPEC-J2 cell strain. The cell strain is preserved in the China Center for Type Culture Collection, the preservation name is a porcine small intestine epithelial cell line R58-WT-IPEC, the Latin name is Sus scrofa, and the preservation number is CCTCC NO: C202425. The invention discloses a key effect of the PEDV N protein in a virus replication stage, and provides application of the PEDV N protein as a target spot in regulation and control of PEDV infection. Compared with a wild-type IPEC-J2 cell line, the cell line provided by the invention has a remarkable promotion effect, can solve the problem of poor proliferation of PEDV (porcine epidemic diarrhea virus) in the IPEC-J2 cell line, and further improves the application possibility of the IPEC-J2 cell line in virus separation and propagation.
Owner:ZHEJIANG UNIV +2

Use of FOXK1 inhibitors for the treatment of inflammatory autoimmune diseases

Targeting the ability of T cells to enhance aerobic glycolysis upon TCR stimulation or glucose supplementation represents an attractive strategy for the treatment of autoimmune diseases. Using a quantitative phosphoproteomic approach, the inventors have identified a new transcription factor called Foxk1 as being highly phosphorylated in T cells upon T Cell Receptor (TCR) engagement. The results also indicate that Foxk1 phosphorylation and nuclear translocation is dependent of the AKT-mTOR kinase activities. Using T-cell specific Foxk1 deficient mice (Foxk1- / -), the inventors demonstrated that Foxk1 is required for full T cell activation. Foxk1-deficient T cells exhibited reduced proliferation and cytokine secretion following TCR stimulation. Furthermore, T cells from Foxk1- / - mice were less prone to acquire an effector like phenotype than wild-type cells when challenged in vivo. Altogether, these results indicated that targeting can be envisioned to reduce auto-immune reactions. Thus, the present invention relates to the use of Foxk1 inhibitors for the treatment of inflammatory autoimmune diseases.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +3

Mesenchymal stem cell with enhanced targeted tumor infiltration ability, and use thereof

Provided are a mesenchymal stem cell (MSC) with an enhanced targeted tumor infiltration ability, and the use thereof. The MSC with an enhanced targeted tumor infiltration ability comprises a polynucleotide encoding an NKG2DL-targeting chimeric antigen receptor. The provided MSC with an enhanced targeted tumor infiltration ability can not only normally overexpress the NKG2DL-targeting chimeric antigen receptor, but also has a better solid tumor targeting property, thus being able to effectively break through solid tumor microenvironments and enter the interior of tumors. Compared to wild-type MSC cells, the MSC has a better retention ability at the tumor site, which enhances the survival ability thereof at the tumor site, thereby enabling the MSC to exert a more long-acting and sustained tumor inhibitory effect at the tumor site and further promoting the use of the MSC in the field of solid tumor treatment.
Owner:SHANGHAI PINPOINT MEDICAL TECH CO LTD